New hope for Sjogren's: oral drug tofacitinib under safety review
NCT ID NCT04496960
First seen Jan 11, 2026 · Last updated May 05, 2026 · Updated 21 times
Summary
This early-phase trial evaluated the safety of tofacitinib, an oral drug that targets inflammation, in 23 adults with mild-to-moderate Sjogren's syndrome. Participants took the drug or a placebo for 168 days and were monitored for side effects. The goal was to see if tofacitinib is safe enough to pursue as a potential treatment for this autoimmune disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.